For more information about any of the clinical trials listed here or to participate, please call 1-646-825-6328.

Clinical Trials by Topic

Urinary Incontinence

Erectile Dysfunction

Benign Prostatic Hyperplasia (BPH)

Healthy Subjects

Urinary Incontinence

Randomized Double-blind Trial of Intravesical Injection of Botox® versus Ditropan XL® for Neurogenic Detrusor Overactivity and Urinary Incontinence Related to Neurologic Disease – BTX0509

Principal Investigator: Victor Nitti, MD

The purpose of this study is to examine whether BOTOX, when injected into the bladder, can lessen detrusor muscle tightening and reduce urinary incontinence in comparison to the effect demonstrated by Ditropan XL. Ditropan XL, which is FDA approved, increases bladder capacity and decreases the urgency and frequency of both incontinent episodes and voluntary urination. BOTOX blocks neuromuscular function in the area into which it is injected.

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Response Study of the Safety and Efficacy of a Single Treatment of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Idiopathic Overactive Bladder with Urge Incontinence (Allergan Study 191622-077)

Principal Investigator: Victor Nitti, MD

The purpose of this study is to investigate whether injections of BOTOX into the bladder are safe and effective in reducing incontinence due to idiopathic overactive bladder.

A Phase 1 Multicenter Study Evaluating the Safety and Potential Activity of Three Escalating Doses of hMaxi-K Gene Transfer in Female Participants With Overactive Bladder Syndrome and Detrusor Overactivity: Double Blind, Imbalanced Placebo Controlled Design Within 3 Sequential Active Treatment Groups

Principal Investigator: Andrew McCullough, MD

The purpose of this gene transfer study is to determine if it is safe to inject a single dose of the gene therapy directly into the bladder to treat overactive bladder syndrome.

Top of Page

Erectile Dysfunction

Clinical Study to Evaluate the Ability of MUSE® to Decrease Erectile Function Recovery Time in Post-radical Prostatectomy Patients

Principal Investigator: Andrew McCullough, MD

The purpose of this study is to test the ability of MUSE®, a medicated pellet that is inserted into the urethra (the opening at the end of the penis) for the treatment of erectile dysfunction, to shorten the time for return of normal erectile function as well as to decrease the time required for you to respond to Viagra. Another objective is to test the ability of Viagra to shorten the time for return of normal erectile function, and a third objective is to compare the ability of MUSE and Viagra to shorten the time for return of normal erectile function. Only men having a Radical Prostatectomy for cancer of the prostate are candidates for this study.

Top of Page

Benign Prostatic Hyperplasia (BPH)

Cetrorelix pamoate Intermittent IM Dosage Regimens in Patients with Symptomatic BPH: a 1 Year Placebo-Controlled Efficacy Study and Long-Term Safety Assessment.

Principal Investigator: Andrew McCullough, MD

The purpose of this research is to study how Cetrorelix pamoate, an investigational drug, affects urinary symptoms in men with benign prostate hyperplasia (BPH). Testosterone is a hormone produced in the body that stimulates the prostate. It is believed that by decreasing testosterone levels with cetrorelix the prostate will become smaller, making it easier to urinate.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy,Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 wks in Men w/Signs & Symptoms of BPH

Principal Investigator: Andrew McCullough, MD

The purpose of this study is to determine if Tadalafil (Cialis), which is currently sold worldwide to treat erectile dysfunction (ED) is a possible treatment for the signs and symptoms of an enlarged prostate.

Top of Page

Healthy Subjects

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Spermatogenesis in Healthy Male Subjects During Administration of BMS-562086

Principal Investigator: Andrew McCullough, MD

The purpose of this research is to study the effects of an investigational drug, BMS-562086, on spermatogenesis in healthy men. BMS-562086 is an investigational drug being developed for use in depression. This is a phase I study to determine the safety of this drug’s use on spermatogenesis and fertility.

A Pilot Study To Assess The Level of Penile Oxygen In The Flaccid Penis With The Odissey Oximeter, In Men With And With And Without Erectile Dysfunction

Principal Investigator: Andrew McCullough, MD

The purpose of this study is to use an FDA approved “non invasive” measuring device to measure the level of oxygen in the limp (flaccid) and firm (erect) penis. Numerous studies have revealed that the maintenance of normal function of the penis requires intermittent high levels of oxygen in the tissues of the penis. This has been shown in human and animal studies. Penile oxygen levels will be linked with your level of erectile function and other factors such as age,vital signs, race and heart disease risk factors such as diabetes,weight, smoking, hypertension, hyperlipidemia, depression and medications that you might be taking.

Top of Page